Stem Cell Research & Therapy in 2012

The benefits of open access publication were reviewed in last year's anniversary editorial [2]. In this editorial, we would like to present the recent progress on important issues that influence an author's decision on where to submit his or her manuscript.Stem Cell Research & Therapy is now indexed by MEDLINE, the premier bibliographic database of the US National Library of Medicine. Each article record is indexed by using MeSH (Medical Subject Headings) terms, and thus the articles are highly accessible via PubMed. Readers can click straight through from PubMed to the Stem Cell Research & Therapy website to read the open-access research articles without having to register or sign in. The final published version of all articles is automatically deposited in PubMed Central; research articles are publicly available immediately upon publication, whereas subscription content, such as reviews and commentaries, becomes available a year after publication.Thomson Reuters (formerly the Institute for Scientific Information) (New York, NY, USA) has accepted Stem Cell Research & Therapy for tracking from volume 1, issue 1, and the journal's first (partial) impact factor is expected in the 2011 Journal Citation Report, which is to be published this summer. The early acceptance of Stem Cell Research & Therapy is an indication of the journal's success in its first few years of existence.The journal received over 19,000 article accesses via the website in March 2012 and this figure has been growing each month. The two most accessed research articles published in 2011 have both received over 5,000 accesses so far; Jung Lim and colleagues [3] studied the effects of mesenchymal stem cells in a rat model of cerebral ischemia, and Alan Nixon's group [4] used fetal-derived embryonic-like stem cells to treat tendon injury in horses.A review by editorial board member Christian Jorgensen and colleagues [5] on immunosuppression by mesenchymal stem cells remains our all-time most accessed ar